Fund IV company Cardior Pharmaceuticals acquired by Novo Nordisk
Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart. The company’s therapeutic approach targets distinctive non-coding RNAs as a platform for addressing root causes of cardiac dysfunctions with an aim to achieve lasting patient impact.
Press inquiries should be adressed to:
Recent Comments